Literature DB >> 16460721

Rapid measurement of S-100B serum protein levels by Elecsys S100 immunoassay in patients undergoing carotid artery stenting or endarterectomy.

Thomas Mussack1, Volker Klauss, Volker Ruppert, Cornelia Gippner-Steppert, Peter Biberthaler, Uwe Schiemann, Ulrich Hoffmann, Marianne Jochum.   

Abstract

OBJECTIVES: This study was designed to apply the rapid Elecsys S100 immunoassay for real-time measurement of S100 protein serum levels indicating acute brain damage in patients undergoing carotid artery stenting (CAS) or endarterectomy (CEA). DESIGN AND METHODS: Data of 14 CAS patients were compared to those of 43 CEA and 14 control patients undergoing coronary angiography (CA). S100 serum levels were measured by the full-automatic Elecsys S100 immunoassay and compared to those obtained by the well-established LIA-mat S100 system.
RESULTS: In contrast to CAS and CA patients, median S100 serum levels of CEA patients significantly increased to 0.24 ng/mL before declamping, but subsequently returned to baseline. Three CEA patients with neurological deficits showed sustained elevated S100 levels 6 h after extubation. Absolute S100 values were not significantly different between the two methods. Bland-Altman plot analyses displayed a good agreement, mostly indicating slightly smaller values applying the Elecsys S100 system.
CONCLUSIONS: The Elecsys S100 system appears to be suitable for rapid real-time detection of neurological deficits in patients undergoing CAS and CEA. Persistent elevations of Elecsys S100 levels during CEA were associated with prolonged neurological disorders, whereas transient increases seem to represent impaired blood-brain barrier integrity without neurological deficits.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16460721     DOI: 10.1016/j.clinbiochem.2005.12.007

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  8 in total

1.  Homogeneous immunosubtraction integrated with sample preparation enabled by a microfluidic format.

Authors:  Akwasi A Apori; Amy E Herr
Journal:  Anal Chem       Date:  2011-03-04       Impact factor: 6.986

2.  Secondary peaks of S100B in serum relate to subsequent radiological pathology in traumatic brain injury.

Authors:  Eric P Thelin; David W Nelson; Bo-Michael Bellander
Journal:  Neurocrit Care       Date:  2014-04       Impact factor: 3.210

3.  Serum S100B levels after meningioma surgery: A comparison of two laboratory assays.

Authors:  Eyal Itshayek; Jeremy D Kark; Haim Ovadia; Carolyn F Weiniger; Yigal Shoshan; Sharon Einav
Journal:  BMC Clin Pathol       Date:  2008-09-19

4.  A simple electrochemical immunosensor based on a chitosan/reduced graphene oxide nanocomposite for sensitive detection of biomarkers of malignant melanoma.

Authors:  Huihua Zhang; Hui Qu; Jingbo Cui; Linxia Duan
Journal:  RSC Adv       Date:  2022-09-12       Impact factor: 4.036

Review 5.  Reliability of S100B in predicting severity of central nervous system injury.

Authors:  Stephen M Bloomfield; James McKinney; Les Smith; Jonathan Brisman
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.532

6.  Kinetic modelling of serum S100b after traumatic brain injury.

Authors:  A Ercole; E P Thelin; A Holst; B M Bellander; D W Nelson
Journal:  BMC Neurol       Date:  2016-06-17       Impact factor: 2.474

Review 7.  A review of the clinical utility of serum S100B protein levels in the assessment of traumatic brain injury.

Authors:  Eric Peter Thelin; David W Nelson; Bo-Michael Bellander
Journal:  Acta Neurochir (Wien)       Date:  2016-12-12       Impact factor: 2.216

8.  Utility of neuron-specific enolase in traumatic brain injury; relations to S100B levels, outcome, and extracranial injury severity.

Authors:  Eric Peter Thelin; Emma Jeppsson; Arvid Frostell; Mikael Svensson; Stefania Mondello; Bo-Michael Bellander; David W Nelson
Journal:  Crit Care       Date:  2016-09-08       Impact factor: 9.097

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.